www.3sbio.com 提示:

本信息仅供医学专业人士参考,如果您是医学专业人士,请点击确定后进入。 如果不是,请点击取消。

取消 确定

Strive to enable biopharmaceuticals created and
manufactured by China to benefit patients worldwide

Overview of the international registration and marketing of 3SBio Group products

At present, 3SBio products that are registered overseas include Etanercept, TPIAO, EPIAO, Intefen and SEPO, etc. The registration has covered nearly 40 countries and regions around the world, with the business and customer scope basically covering all the developing countries. After years of hard work, these products have also been registered and listed in many countries.

  • Latin American region with Mexico, Colombia, Brazil, etc. being the centers
  • South Asia Region with India and Pakistan being the centers
  • East Asian region with Thailand, Bangladesh, Sri Lanka and Philippines being centers
  • The Commonwealth of the Independent States (CIS) region with Russia, Belarus and Ukraine being centers
  • Middle Eastern & Northern Africa (MENA) region with Turkey and Egypt being centers

Summary of the products that have been registered and listed overseas

Etanercept has obtained marketing approval from total 10 countries, and it is under registration application in over 20 countries.

Countries
Colombia
Mexico
Salvador
Paraguay
India
Panama
Ecuador
Bolivia
Bengal
Cambodia
Thailand

TPIAO has obtained marketing approval from total 5 countries, and it is under registration application in nearly 10 countries.

Countries
Dominica
Philippines
Paraguay
Costa Rica
Ukraine
Thailand

EPIAO has obtained marketing approval from total 21 countries, and it is under registration application in nearly 20 countries.

Countries
Mongolia
Brazil
Egypt
Trinidad and Tobago
Dominica
Guatemala
Thailand
Sri Lanka
Pakistan
Colombia
Salvador
Laos
Gabon
Paraguay
Cote d'Ivoire
Benin
Togo
Senegal
Burma
Cambodia
Uzbekistan

Intefen has obtained marketing approval from total 3 countries, and it is under registration application in nearly 10 countries.

Countries
Brazil
Pakistan
Ukraine

SEPO has obtained marketing approval from total 6 countries, and it is under registration application in nearly 10 countries.

Countries
Peru
Pakistan
Belarus
India
Philippines
Thailand

Clinical experience (important internationally published papers)

  • Application of Etanar® Therapy in Patients with Rheumatoid Arthritis

    Published at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR), Atlanta, Georgia, USA, in November 10, 2010.


    Abstract 1811. In the “real life” environment, the 20-week efficacy and safety analysis was conducted in the 110 patients who received Etanar® (25 mg, subcutaneous injection, twice a week) in combination with multiple DMARD anti-RA treatment for a long time.

  • ETANAR - Generic drug Etanercept is as effective as adalimumab and infliximab in treating a group of patients with rheumatoid arthritis

    This article was published as a poster in EULARL 2015 (Rome, Italy) (P. Santos-Moreno et al. Ann Rheum Dis 2015; 74:789-790).


    The descriptive cross-sectional study included 158 RA patients who visited at least 6 rheumatologists within the past 24 months, and respectively received adalimumab (61 (38.6%), infliximab (35 (22.2 %) and etanercept biosimilar products (62 (39.2%) (Etanar® CP Guojian Pharmaceutical Co., Ltd. (China)).

  • Clinical Outcomes of Etanar - a New Biotype of rhTNFR:Fc in Colombian Patients with Rheumatoid Arthritis

    (PISantos-Moreno, G. Sánchez, D. Gómez, C. Castro. Clinical and Experimental Rheumatology, 2015; 33: 858-862.) A multicenter observational cohort study evaluated the clinical reactions at the 12th month in 105 RA patients treated with Etanar (rhTNFR:Fc) and the incidence of the adverse reactions was recorded.

  • Comparison of the direct effects of three anti-tumor necrosis factor biologics in the cohort of patients with rheumatoid arthritis

    (Pedro Santos-Moreno, Guillermo Sánchez, Danny Gómez. et al; JCR-Journal of Clinical Rheumatology, 2016; 22 (2):57-62) The observational retrospective cohort study compared the clinical reactions at 36 months after treatment in 307 RA patients who received Etanercept (Etanar®), infliximab (Remecade®) or adalimumab (Humira®) and evaluated the adverse events.

International Business Department

Address: No. 399 Libing Road, Zhangjiang Hi-Tech Park, Shanghai, China. Post code: 201203

Email Address : international@3sbio.com

Tel: +86-21-50791399